Factors related to fatalities and clinical progression of Crimean-Congo hemorrhagic fever patients and the effects of IL 28-B gene polymorphism
Mortality rates of Crimean-Congo hemorrhagic fever (CCHF) vary from 5% to 80%. However, there is no clear information available about why this disease is fatal for some people while others recover. In this study, the factors related to fatalities and serious clinical progression of CCHF patients and the correlation between serious prognosis and IL 28-B gene polymorphism were investigated. The study included 107 patients with a preliminary diagnosis of CCHF, and the patients were found positive for CCHFV RNA based on polymerase chain reaction (PCR) analysis. The IL 28-B rs12979860 polymorphism was identified by PCR “restriction fragment length polymorphism” (PCR-RFLP) analysis using blood samples from the patients. In addition to the IL 28-B analysis results, a variety of data along with laboratory records obtained during the hospital stay were evaluated using statistical analysis. Of the 107 cases, nine were fatal (8.4%), while the other patients recovered and were discharged. Twenty-four patients had the CC genotype (22.43%), 64 had the CT genotype (59.81%), and 19 had the TT genotype (17.76%). Of the nine patients who died, three had the CC genotype (33.33%) and six had the CT genotype (66.67%). None of the patients who died had the TT genotype. Symptoms and findings of diarrhea, abdominal pain, hemorrhage, and rash were more common in fatal cases than in non-fatal cases. The IL 28-B rs12979860 polymorphism was not found to have a statistically significant correlation with fatality or symptoms indicating serious clinical progression in CCHF patients. As has been observed in previous studies, our study showed that leukocytosis, abdominal pain and diarrhea were more common in fatal cases.
FYA: writing, data collection. HŞB: materials and methods, revision. AR: materials and methods, genetic experiments, revision. AA: data collection. ÖG: writing, data collection, materials and methods. FD: writing, data collection, materials and methods.
Materials used for genetic analysis were obtained from the medical biology laboratory. Blood values evaluated in the study were the results of routine diagnosis/treatment.
Compliance with ethical standards
This study was evaluated by the Gaziosmanpaşa University Faculty of Medicine Research and Application Hospital Clinic Ethics Committee on 24/09/2013 at meeting 18, and permission was granted with decision 371, dated 01/11/2013.
Human/animal rights statement
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
Availability of data and material
The datasets used and/or analyzed in the current study are available from the corresponding author on reasonable request.
Conflict of interest
The authors declare that there is no conflict of interest of any type, that no financial disclosure information is relevant, and that they take full responsibility for this publication’s results and their interpretations.
- 1.Centers for Disease Control and Prevention (1988) Management of patients with suspected viral hemorrhagic fever. MMWR 37:1–16Google Scholar
- 2.Zivcec M, Safronetz D, Scott D, Robertson S, Ebihara H, Feldmann H (2013) Lethal Crimean-Congo hemorrhagic fever virus infection in interferon α/β receptor knockout mice is associated with high viral loads, proinflammatory responses, and coagulopathy. J Infect Dis 207:1909–1921CrossRefGoogle Scholar
- 3.Spengler JR, Kelly Keating M, McElroy AK, Zivcec M, Coleman-McCray JD, Harmon JR, Bollweg BC, Goldsmith CS, Bergeron E, Keck JG, Zaki SR, Nichol ST, Spiropoulou CF (2017) Crimean-Congo hemorrhagic fever in humanized mice reveals glial cells as primary targets of neurological infection. J Infect Dis 216:1386–1397CrossRefGoogle Scholar
- 5.Bakir M (2004) Kırım-Kongo hemorajik ateşi. ANKEM Dergisi 18:90–93Google Scholar
- 7.Watts DM, Ksiazeck TG, Linthicum KJ, Hoogstraal H (1988) Crimean-Congo hemorrhagic fever. In: Monath TP (ed) The arboviruses, epidemiology and ecology. CRC Press, Boca Raton, pp 177–222Google Scholar
- 10.Akinci E (2008) Kırım Kongo kanamalı ateşi: Korunma ve kontrol. Türkiye Zoonotik Hastalıklar Sempozyomu, pp 79–87Google Scholar
- 16.Bordi L, Lalle E, Lapa D, Caglioti C, Quartu S, Capobianchi M, Castilletti C (2013) Type III interferon (IFN-lambda) antagonizes the antiviral activity of interferon-alpha in vitro. J Biol Regul Homeost Agents 27:1001–1009Google Scholar
- 17.Dornhoff H, Siebler J, Neurath MF (2011) Potential role of interferon-lambda in the treatment of inflammation and cancer: an update. Int J Interferon Cytokine Mediat Res 3:51–57Google Scholar
- 20.Biswas A, Firdaus R, Gupta D, Ghosh M, Saha K, Chowdhury P, Bhattacharyya M, Sadhukhan PC (2017) Interferon λ3 gene (IL28B) is associated with spontaneous or treatment-induced viral clearance in hepatitis C virus-infected multitransfused patients with thalassemia. Transfusion 57:1376–1384CrossRefGoogle Scholar
- 24.Assone T, de Souza FV, Gaester KO, Fonseca LA, Luiz Odo C, Malta F, Pinho JR, Goncalves Fde T, Duarte AJ, de Oliveira AC, Casseb J (2014) IL28B gene polymorphism SNP rs8099917 genotype GG is associated with HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in HTLV-1 carriers. PLoS Negl Trop Dis 8:e3199CrossRefGoogle Scholar
- 27.Spada E, Amoroso P, Taliani G, Zuccaro O, Chiriacò P, Maio P, Maio G, Esposito ML, Mariano C, Rinaldi R, Bellissima P, Tosti ME, Del Porto P, Francavilla R, Mellace V, Garbuglia AR, Folgori A, Mele A, For the Acute Hepatitis Italian Study G, Buonocore S, Lettieri G, Pierri P, Cosco L, Ferraro T, Scognamiglio P, Capobianchi MR, Baldi U, Montesano F, Audino G, De Stefano C, Caterini A, Cuccia M, Girelli G, Perrone P, Laurenti L, Piccolella E, Scotta C, Cortese R, Nicosia A, Vitelli A (2013) Role of IL28B gene polymorphism and cell-mediated immunity in spontaneous resolution of acute hepatitis C. Clin Infect Dis 57:803–811CrossRefGoogle Scholar
- 28.Echeverría N, Chiodi D, López P, Sanchez Ciceron A, Angulo J, López-Lastra M, Silvera P, Canavesi A, Bianchi C, Colistro V, Cristina J, Hernandez N, Moreno P (2018) IL28B gene polymorphism rs12979860, but not rs8099917, contributes to the occurrence of chronic HCV infection in Uruguayan patients. Virol J 15:40CrossRefGoogle Scholar
- 29.Karkhane M, Mohebbi SR, Azimzadeh P, Saeedi Niasar M, Sarbazi MR, Sharifian A, Alizadeh AM (2016) Lack of association between interleukin 28B gene polymorphisms (rs8099917G/T, rs12979860 C/T) and susceptibility to chronic hepatitis C virus infection, Tehran, Iran. Gastroenterol Hepatol Bed Bench 9:S29–S35Google Scholar
- 30.Bordi L, Lalle E, Caglioti C, Travaglini D, Lapa D, Marsella P, Quartu S, Kis Z, Arien KK, Huemer HP, Meschi S, Ippolito G, Di Caro A, Capobianchi MR, Castilletti C (2015) Antagonistic antiviral activity between IFN-Lambda and IFN-Alpha against lethal Crimean-Congo hemorrhagic fever virus in vitro. PLoS One 10:e0116816CrossRefGoogle Scholar
- 33.Khattab MA, Abdelghany HM, Ramzy MM, Khairy RM (2016) Impact of IL28B gene polymorphisms rs8099917 and rs12980275 on response to pegylated interferon-α/ribavirin therapy in chronic hepatitis C genotype 4 patients. J Biomed Res 30:40–45Google Scholar
- 34.Khairy M, Fouad R, Mabrouk M, El-Akel W, Awad AB, Salama R, Elnegouly M, Shaker O (2013) The impact of interleukin 28B gene polymorphism on the virological response to combined pegylated interferon and ribavirin therapy in chronic HCV genotype 4 infected Egyptian patients using data mining analysis. Hepat Mon 13:e10509CrossRefGoogle Scholar
- 35.Safarnezhad Tameshkel F, Karbalaie Niya MH, Sohrabi M, Panahi M, Zamani F, Imanzade F, Rakhshani N (2016) Polymorphism of IL-28B gene (rs12979860) in HCV genotype 1patients treated by pegylated interferon and ribavirin. Iran J Pathol 11:216–221Google Scholar
- 43.Bakir M, Engin A, Gozel MG, Elaldi N, Kilickap S, Cinar Z (2012) A new perspective to determine the severity of cases with Crimean-Congo hemorrhagic fever. J Vector Borne Dis 49:105–110Google Scholar